El Kassas Mohamed, Elbaz Tamer, Abd El Latif Yasmeen, Esmat Gamal
a Endemic Medicine Department, Faculty of Medicine , Helwan University , Cairo , Egypt.
b Endemic Hepatogastroenterology, Faculty of Medicine , Cairo University , Cairo , Egypt.
Expert Rev Clin Pharmacol. 2016 Nov;9(11):1413-1421. doi: 10.1080/17512433.2016.1233813. Epub 2016 Sep 26.
During the last few years, treatment of hepatitis C virus (HCV) revolutionized with the appearance of direct antiviral agents especially for patients with HCV genotypes 1 and 4 infections. Elbasvir (NS5A inhibitor) and grazoprevir (NS3/4A protease inhibitor) are newly developed drugs that are presented in fixed dose combination tablets. Areas covered: This review covers the mechanism of action, pharmacokinetic and pharmacodynamics properties, clinical uses, safety and efficacy of elbasvir/grazoprevir in managing a wide variety of easy and difficult to treat populations (such as presence of cirrhosis, treatment experienced, co-infection with HIV and patients with inherited blood disorders). Expert commentary: Elbasvir/grazoprevir combination showed great efficacy with high rates of sustained virological response rates in genotypes 1 and 4 HCV infection. In addition, it retained a good safety profile and is generally well tolerated.
在过去几年中，随着直接抗病毒药物的出现，丙型肝炎病毒（HCV）的治疗发生了革命性变化，特别是对于HCV 1型和4型感染的患者。艾尔巴韦（NS5A抑制剂）和格拉瑞韦（NS3/4A蛋白酶抑制剂）是新开发的药物，以固定剂量复方片剂形式提供。涵盖领域：本综述涵盖了艾尔巴韦/格拉瑞韦在治疗各种易治和难治人群（如肝硬化患者、经治患者、合并HIV感染以及遗传性血液疾病患者）中的作用机制、药代动力学和药效学特性、临床用途、安全性和疗效。专家评论：艾尔巴韦/格拉瑞韦组合在1型和4型HCV感染中显示出很高的疗效，持续病毒学应答率很高。此外，它保持了良好的安全性，总体耐受性良好。
